Electromed, Inc. — Q1 Fiscal 2012 Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest system. Products are sold through home-care, institutional, government and international channels. This report covers the three months ended September 30, 2011, compared with the three months ended September 30, 2010. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net revenues | $5.379 million | $4.165 million | Up 29.1% |
| Gross profit | $4.058 million | $2.934 million | Up 38.3% |
| Gross margin | 75.4% | 70.4% | Up 5.0 percentage points |
| Operating income | $452,000 | $248,000 | Up 82.6% |
| Net income | $246,000 | $112,000 | Up 119.1% |
| Net margin | 4.6% | 2.7% | Up 1.9 percentage points |
| Diluted EPS | $0.03 | $0.02 | Increase |
| Net cash used in operating activities | $(823,000) | $(61,000) | Greater use of cash |
Home-care revenue increased 34.9% to approximately $5.132 million, supported by referrals increasing 17.6% to 696 and expansion of the sales force from 18 to 23 full-time equivalents. Government and institutional revenue increased 3.4% to approximately $210,000. International revenue declined 76.7% to approximately $37,000, primarily because of lower European and Asian sales.
SG&A expense increased 36.6% to approximately $3.398 million, principally because of higher staffing, sales-force support, travel, marketing and professional fees. Research and development expense increased 5.1% to approximately $208,000, or 3.9% of revenue. Interest expense declined approximately 25.8% to $44,000. The effective tax rate was approximately 39.9%.
Liquidity, Debt and Balance Sheet
- Cash and cash equivalents declined from $4.092 million at June 30, 2011 to $2.946 million at September 30, 2011.
- Accounts receivable increased to $10.400 million from $9.593 million, and inventories increased to $2.164 million from $1.856 million.
- Total assets were $21.168 million; total liabilities were $6.161 million; shareholders’ equity was $15.007 million.
- At September 30, 2011, debt under the U.S. Bank facility totaled approximately $3.614 million, including $1.768 million drawn on the revolving line and approximately $1.846 million of term debt.
- Reported net unused revolving-line availability was approximately $1.732 million at September 30, 2011.
- On November 8, 2011, the company amended and restated its credit facility, increasing the revolving line to $6.0 million and providing $2.520 million of term debt. The revolving facility expires December 31, 2012, if not renewed earlier.
- The credit agreement includes fixed-charge coverage and cash-flow leverage requirements, restrictions on dividends and other customary operating, investment and financing limitations. Management stated that the company was in compliance with the prior facility’s requirements as of September 30, 2011.
Operating cash flow was negative primarily because of increases in accounts receivable, inventory and prepaid expenses, which management attributed to sales growth, expanded operations and the normal delay in collecting amounts from third-party payers. Investing cash outflows were $237,000, including $215,000 for property and equipment and $22,000 for patent-related costs. Financing cash outflows were $86,000, primarily reflecting term-debt principal payments.
Material Changes and Management Commentary
- Management attributed revenue growth to a larger sales organization, broader territory coverage and increased market penetration.
- Management cautioned that the 75.4% gross margin was aided by an unusually favorable referral and reimbursement mix and should not be viewed as indicative of a sustained long-term margin level.
- Management expects to spend at least 5.0% of sales on research and development for the foreseeable future.
- Management believes cash and available borrowings will meet liquidity needs for at least the next twelve months, but stated that additional financing may be required for unexpected capital needs or insufficient operating cash flow.
- The company leased and began converting approximately 10,000 square feet of additional office space; approximately $99,000 of related conversion costs was included in property and equipment spending.
- The former chief financial officer retired effective October 18, 2011. The company entered into a separation arrangement providing approximately $27,600 for accrued vacation and approximately $147,000 of separation pay and a prorated bonus, subject to the agreement’s terms.
Risks, Contingencies and Unusual Items
- Key risks include reimbursement changes involving Medicare, Medicaid and private insurers; regulatory requirements; competition; international-market conditions; sales-force execution; intellectual-property protection; litigation; credit-market conditions; and general economic conditions.
- The company’s prior trademark litigation with Hill-Rom was settled in September 2010 without a material impact, and the settlement does not prohibit continued use of the SmartVest trademark. Settlement terms are confidential.
- The company records a warranty reserve for product obligations. The reserve increased from $444,000 at June 30, 2011 to $475,000 at September 30, 2011.
- The company has related-party arrangements, including approximately $90,000 of quarterly research and development services from a provider affiliated with company directors and the chief executive officer, and approximately $144,000 of purchases from a parts supplier whose founder became a company director.
- The filing states that the company has no off-balance-sheet arrangements and no known undisclosed litigation expected to have a material adverse effect.
- Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter.
Investor Verification Items
- Verify whether the elevated gross margin normalizes as reimbursement and referral mix changes.
- Monitor collections, accounts receivable and inventory growth because operating cash flow was substantially negative despite higher earnings.
- Review borrowing-base availability, covenant compliance and maturity/refinancing risk under the amended credit facility.
- Assess whether expanded sales, reimbursement and administrative staffing produces sustained revenue growth sufficient to cover higher operating expenses.
- Track international revenue recovery and exposure to European economic and reimbursement conditions.
- Review the terms and future cash impact of executive separation and change-in-control arrangements.
- Evaluate the effect of related-party transactions and warranty obligations on future expenses and cash flows.